SG11202110789VA - Gene therapy for eye pathologies - Google Patents
Gene therapy for eye pathologiesInfo
- Publication number
- SG11202110789VA SG11202110789VA SG11202110789VA SG11202110789VA SG11202110789VA SG 11202110789V A SG11202110789V A SG 11202110789VA SG 11202110789V A SG11202110789V A SG 11202110789VA SG 11202110789V A SG11202110789V A SG 11202110789VA SG 11202110789V A SG11202110789V A SG 11202110789VA
- Authority
- SG
- Singapore
- Prior art keywords
- gene therapy
- eye pathologies
- pathologies
- eye
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/04—Uses of viruses as vector in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828949P | 2019-04-03 | 2019-04-03 | |
US201962856533P | 2019-06-03 | 2019-06-03 | |
US201962946158P | 2019-12-10 | 2019-12-10 | |
PCT/US2020/026356 WO2020206098A1 (en) | 2019-04-03 | 2020-04-02 | Gene therapy for eye pathologies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110789VA true SG11202110789VA (en) | 2021-10-28 |
Family
ID=70480820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110789VA SG11202110789VA (en) | 2019-04-03 | 2020-04-02 | Gene therapy for eye pathologies |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220143221A1 (en) |
EP (1) | EP3946467A1 (en) |
JP (1) | JP2022521851A (en) |
KR (1) | KR20220004987A (en) |
CN (1) | CN113966236A (en) |
AU (1) | AU2020253462A1 (en) |
BR (1) | BR112021019825A2 (en) |
CA (1) | CA3135843A1 (en) |
IL (1) | IL286825A (en) |
MX (1) | MX2021011889A (en) |
SG (1) | SG11202110789VA (en) |
TW (1) | TW202102679A (en) |
WO (1) | WO2020206098A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3452103A1 (en) | 2016-04-15 | 2019-03-13 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
BR112020012336A2 (en) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | ADMINISTRATION OF AAV MEDIATED THERAPEUTIC ANTIBODIES FOR INTERNAL EAR |
WO2020222858A1 (en) * | 2019-04-27 | 2020-11-05 | Ocugen, Inc. | Adeno-associated virus vector mediated gene therapy for ophthalmic diseases |
CN111826386B (en) * | 2020-07-30 | 2022-02-01 | 西南大学 | Fusion gene for regulating and controlling color development of cotton fibers, expression vector and application thereof |
IL301643A (en) * | 2020-10-07 | 2023-05-01 | Regenxbio Inc | Gene therapy for ocular manifestations of cln2 disease |
EP4333903A1 (en) * | 2021-05-03 | 2024-03-13 | North Carolina State University | Compositions and methods related to the treatment of ocular diseases in equines |
WO2022263841A1 (en) * | 2021-06-18 | 2022-12-22 | Ikarovec Limited | Retinal disorders |
WO2023133561A1 (en) * | 2022-01-09 | 2023-07-13 | Kriya Therapeutics, Inc. | Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same |
WO2024048688A1 (en) * | 2022-08-31 | 2024-03-07 | 国立大学法人京都大学 | Light-responsive modified opsin |
WO2024073669A1 (en) | 2022-09-30 | 2024-04-04 | Regenxbio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
CN116965768B (en) * | 2023-07-07 | 2024-01-19 | 中山大学中山眼科中心 | System for automatically and quantitatively analyzing degree of inflammation of anterior chamber in eye |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US878575A (en) | 1906-12-31 | 1908-02-11 | Isaac Stevenson | Ore dredging and separating apparatus. |
EP0804561B1 (en) | 1993-02-12 | 2009-12-30 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
CA2209183A1 (en) | 1994-12-29 | 1996-07-11 | Joel L. Pomerantz | Chimeric dna-binding proteins |
WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
AU9036198A (en) | 1997-08-26 | 1999-03-16 | Ariad Gene Therapeutics, Inc. | Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain |
JP2001514007A (en) | 1997-08-27 | 2001-09-11 | アリアド ジーン セラピューティクス インコーポレイテッド | Chimeric transcription activators and compositions and uses related thereto |
AU755784B2 (en) | 1998-01-15 | 2002-12-19 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using multimeric chimeric proteins |
WO1999041258A1 (en) | 1998-02-13 | 1999-08-19 | President And Fellows Of Harvard College | Novel dimerizing agents, their production and use |
AU781958C (en) | 1999-08-09 | 2006-03-30 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
PT1453547T (en) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor |
US20040208847A1 (en) * | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
ES2648241T3 (en) | 2003-09-30 | 2017-12-29 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus clades (AAV), sequences, vectors containing the same, and uses thereof |
ES2525067T3 (en) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an AAV vector |
JP4495210B2 (en) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | Amplitude error compensator and orthogonality error compensator |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
WO2012057363A1 (en) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | Adeno-associated virus virions for transferring genes into neural cells |
US9409953B2 (en) | 2011-02-10 | 2016-08-09 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
PL3254703T3 (en) | 2011-04-22 | 2020-10-05 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
JP6385920B2 (en) | 2012-05-09 | 2018-09-05 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Adeno-associated virus plasmid and vector |
ES2729166T3 (en) | 2012-05-24 | 2019-10-30 | Altaviz Llc | Viscous fluid injector |
AU2014244167A1 (en) | 2013-03-13 | 2015-10-08 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
WO2015038958A1 (en) | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Selective recovery |
HUE052676T2 (en) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Methods of predicting ancestral virus sequences and uses thereof |
US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
US10064752B2 (en) * | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
US11096822B2 (en) | 2014-09-19 | 2021-08-24 | Oxular Limited | Ophthalmic delivery device |
EP3223760B1 (en) | 2014-11-28 | 2020-01-08 | Visionisti OY | Ocular therapeutics tool |
BR112017017867A2 (en) * | 2015-02-20 | 2018-04-10 | Fond Telethon | methods and compositions for treating genetic eye disease |
JP6920002B2 (en) | 2015-09-17 | 2021-08-18 | オクラー リミテッド | Ophthalmic injection device |
GB201519086D0 (en) * | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
WO2017120601A1 (en) * | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
WO2017158365A2 (en) | 2016-03-16 | 2017-09-21 | Oxular Limited | Ophthalmic delivery device and ophthalmic active agent containing compositions |
SG10202008378UA (en) | 2016-04-15 | 2020-10-29 | Regenxbio Inc | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
EP3452103A1 (en) * | 2016-04-15 | 2019-03-13 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
AU2018342094A1 (en) * | 2017-09-27 | 2020-04-02 | Regenxbio Inc. | Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF Fab |
WO2019090195A1 (en) | 2017-11-04 | 2019-05-09 | Altaviz, Llc | Gas-powered fluid injection system |
US11071824B2 (en) | 2017-11-04 | 2021-07-27 | Altaviz, Llc | Injection devices and methods for making and using them |
-
2020
- 2020-04-02 EP EP20723243.0A patent/EP3946467A1/en active Pending
- 2020-04-02 SG SG11202110789VA patent/SG11202110789VA/en unknown
- 2020-04-02 CN CN202080041009.0A patent/CN113966236A/en active Pending
- 2020-04-02 US US17/600,377 patent/US20220143221A1/en active Pending
- 2020-04-02 KR KR1020217035262A patent/KR20220004987A/en unknown
- 2020-04-02 CA CA3135843A patent/CA3135843A1/en active Pending
- 2020-04-02 BR BR112021019825A patent/BR112021019825A2/en unknown
- 2020-04-02 JP JP2021559062A patent/JP2022521851A/en active Pending
- 2020-04-02 MX MX2021011889A patent/MX2021011889A/en unknown
- 2020-04-02 WO PCT/US2020/026356 patent/WO2020206098A1/en unknown
- 2020-04-02 AU AU2020253462A patent/AU2020253462A1/en active Pending
- 2020-04-06 TW TW109111508A patent/TW202102679A/en unknown
-
2021
- 2021-09-29 IL IL286825A patent/IL286825A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020206098A1 (en) | 2020-10-08 |
EP3946467A1 (en) | 2022-02-09 |
TW202102679A (en) | 2021-01-16 |
BR112021019825A2 (en) | 2021-12-21 |
IL286825A (en) | 2021-10-31 |
AU2020253462A1 (en) | 2021-10-28 |
KR20220004987A (en) | 2022-01-12 |
CN113966236A (en) | 2022-01-21 |
WO2020206098A9 (en) | 2021-02-04 |
US20220143221A1 (en) | 2022-05-12 |
JP2022521851A (en) | 2022-04-12 |
CA3135843A1 (en) | 2020-10-08 |
MX2021011889A (en) | 2021-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286825A (en) | Gene therapy for eye pathologies | |
HK1258518A1 (en) | Gene therapy for ocular disorders | |
IL279685A (en) | Gene therapy | |
PL3612237T3 (en) | Gene therapy | |
GB201900702D0 (en) | Therapy | |
IL280165A (en) | Glucocerebrosidase gene therapy | |
IL287956A (en) | Gene for parthenogenesis | |
EP3638316A4 (en) | Gene therapy for ocular disorders | |
IL268946A (en) | Gene therapy for ocular disorders | |
EP3634986A4 (en) | Gene therapy for ocular disorders | |
GB201707212D0 (en) | Gene therapy for ciliopathies | |
GB201905301D0 (en) | Gene therapy | |
GB201802326D0 (en) | Gene therapy | |
IL287186A (en) | Monitoring gene therapy | |
IL275613A (en) | Gene therapy for eosinohilic disorders | |
GB201817470D0 (en) | Gene therapy | |
EP3931214A4 (en) | Gene therapy for addiction disorders | |
GB201701968D0 (en) | Gene therapy | |
EP3760209C0 (en) | Ischemic-lesion-site-specific gene therapy | |
GB201820982D0 (en) | Gene Therapy | |
GB201817469D0 (en) | Gene therapy for retinal disease | |
GB201811541D0 (en) | Gene therapy | |
EP3717024A4 (en) | Gene therapy for ocular improvement | |
ZA202109745B (en) | Improved ophthalmic apparatus | |
GB201801511D0 (en) | Gene therapy |